INDIA – G-KnowMe, a Bangalore-based informatics startup, has joined forces with researchers at the University of Cambridge and the Cambridge University Hospitals NHS Foundation Trust (CUH) to pioneer an automated workflow for interpreting cancer genome sequencing data. 

The collaboration seeks to streamline the process of analyzing cancers’ entire genomes, bridging the gap between research and clinical management.

As the costs of genome sequencing plummet, its integration into cancer management becomes increasingly pivotal. 

Professor Jean Abraham, Director of the Precision Breast Cancer Institute at the University of Cambridge, highlights the challenge of timely interpretation in making informed clinical decisions. 

She emphasizes the significance of this collaboration in developing clinical interpretation of whole genome sequencing (WGS) data for breast cancer management, stressing the need for advanced automation and artificial intelligence tools.

Tumor profiles contain valuable insights that can inform personalized treatment plans, predict therapy response, identify clinical trial opportunities, and unveil inherited cancer predispositions. However, accessing and interpreting this wealth of genetic information poses significant hurdles.

Nimisha Gupta, Founder of G-KnowMe, highlights the company’s commitment to leveraging expertise in artificial intelligence and cancer biology to facilitate the adoption of large panels in cancer management. 

While G-KnowMe’s existing platform, G-KnowMiner, is utilized by leading diagnostics labs in India for interpreting Next Generation Sequencing (NGS) panel data, the partnership aims to extend its capabilities to analyze WGS data within a clinically relevant timeframe.

This collaboration signifies a crucial step towards enhancing the integration of genomic insights into cancer care, promising to revolutionize the way clinicians approach cancer diagnosis and treatment planning. 

By harnessing cutting-edge technologies and interdisciplinary expertise, G-KnowMe, in partnership with esteemed institutions, is poised to propel the field of precision oncology forward.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook